NDA 215133 · Almatica
Sertraline Hydrochloride
Sertraline Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Oct 4, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
369
75 Phase 3, 32 recruiting
FAERS reports
39,393
27,842 serious, 4,133 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 )
What it is approved for
From the label in effect Oct 2, 2026.
Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following [see Clinical Studies ( 14 )] : Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older Sertraline Hydrochloride (HCl) Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older
Mechanism: Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 4, 2021 Original approval · Type 3 - New Dosage Form LabelLetterReview
- Oct 4, 2021 Original approval · Type 3 - New Dosage Form LetterReview
2 products under this application
- SERTRALINE HYDROCHLORIDE · SERTRALINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
- SERTRALINE HYDROCHLORIDE · SERTRALINE HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sertraline" as an intervention, any sponsor and status, largest first.
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanPivotal-lookingRecruiting
Pakistan Institute of Living and LearningAcademic, hospital or other
NCT07015944 · 26,376 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 30, 2028
Drug: Standardised pharmacological treatment (antidepressants) · For: Major Depressive Disorder (MDD); Breast Cancer Survivor
Sites: Karachi, Pakistan
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Strategic Use of New Generation Antidepressants for DepressionPivotal-lookingCompleted
Kyoto UniversityAcademic, hospital or other
NCT01109693 · 2,011 participants · Start Dec 2010 · Primary completion Sep 2015
Drug: Sertraline; Mirtazapine · For: Unipolar Major Depressive Episode
Sites: Nagoya, Japan; Nangoku, Japan
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,045
- nausea2,693
- headache2,471
- fatigue2,343
- depression2,043
- diarrhoea1,972
- anxiety1,942
- dizziness1,838
- drug interaction1,779
- dyspnoea1,743
- off label use1,633
- vomiting1,525
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 649 |
| 2005 | 737 |
| 2006 | 156 |
| 2007 | 208 |
| 2008 | 274 |
| 2009 | 961 |
| 2010 | 1,788 |
| 2011 | 2,133 |
| 2012 | 2,234 |
| 2013 | 950 |
| 2014 | 1,080 |
| 2015 | 1,601 |
| 2016 | 1,759 |
| 2017 | 1,946 |
| 2018 | 2,186 |
| 2019 | 2,655 |
| 2020 | 2,670 |
| 2021 | 2,466 |
| 2022 | 2,762 |
| 2023 | 2,281 |
| 2024 | 2,555 |
| 2025 | 2,878 |
| 2026 | 2,464 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review.
Wu T, Song F, Cao W, et al. · BMC Psychiatry 2025 · Systematic Review, Comparative Study
- Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.
Mao JJ, Xie SX, Zee J, et al. · Phytomedicine 2015 · Clinical Trial, Phase II, Randomized Controlled Trial
- Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial.
Davis LL, Behl S, Lee D, et al. · JAMA Psychiatry 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder.
Lépine JP, Caillard V, Bisserbe JC, et al. · Am J Psychiatry 2004 · Clinical Trial, Comparative Study
- Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.
Hoskins MD, Bridges J, Sinnerton R, et al. · Eur J Psychotraumatol 2021 · Meta-Analysis, Systematic Review
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.